Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LinearDNA telomerase reverse transcriptase vaccine
- Development stage
- Preclinical
- Lead developer
- LineaRx
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
LinearDNA telomerase reverse transcriptase vaccine is an investigational **DNA cancer vaccine** built on Applied DNA Sciences' PCR-produced LinearDNA platform and encoding **telomerase reverse transcriptase**, a broadly expressed tumor-associated antigen. The vaccine was designed to induce antigen-specific cellular immune responses against **TERT-expressing tumor cells**, functioning as an **anticancer immunotherapy** rather than by directly inhibiting telomerase enzymatic activity. Preclinical reports from Applied DNA Sciences and EvviVax described immunogenicity and antitumor activity in mouse models, and the TERT construct was licensed for **veterinary applications**, particularly development toward **canine B-cell lymphoma**. The available public information identifies it as a platform-derived linear DNA amplicon vaccine candidate and does not indicate marketing approval.
- Other names
- LinearDNA TERT vaccinelinDNA TERT vaccineanti-telomerase reverse transcriptase cancer vaccineTERT DNA vaccine
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on LinearDNA telomerase reverse transcriptase vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LinearDNA telomerase reverse transcriptase vaccine.